Oxipal 0.075 mg/1.5 ml IV Injection

About Oxipal 0.075 mg/1.5 ml IV Injection

Oxipal 0.075 mg/1.5 ml IV comes as a injection with.075 mg/1.5 ml of Palonosetron, from Radiant Pharmaceuticals Ltd. It may also be used for nausea and vomiting after surgery.

There are 16 brands of Palonosetron listed in Bangladesh.

What is Oxipal 0.075 mg/1.5 ml IV Injection?

Oxipal 0.075 mg/1.5 ml IV.075 mg/1.5 ml is a injection product of Radiant Pharmaceuticals Ltd. that contains Palonosetron. It is used for acute and delayed nausea and vomiting, including nausea and vomiting caused by chemotherapy or radiotherapy, and for uncontrolled nausea and vomiting. Oxipal 0.075 mg/1.5 ml IV is an injection that contains Palonosetron, a medicine from the anti-emetic group. The doctor decides whether it is suitable and how it should be taken.

Uses of Oxipal 0.075 mg/1.5 ml IV

It may also be used for nausea and vomiting after surgery. It is an anti-emetic medicine, meaning it acts against nausea and vomiting. It is also used for uncontrolled nausea and vomiting and for nausea and vomiting caused by chemotherapy or radiotherapy. Your doctor will decide if it is right for your situation.

How to use Oxipal 0.075 mg/1.5 ml IV

Oxipal 0.075 mg/1.5 ml IV is given as an injection by a doctor or nurse, usually into a vein. Oxipal 0.075 mg/1.5 ml IV is given as an injection by a healthcare professional. Do not inject it yourself unless a doctor has shown you how. Swallow the injection with a glass of water. Do not change the dose or stop early without asking your doctor. Always follow the instructions of your doctor or nurse.

Side effects of Oxipal 0.075 mg/1.5 ml IV

Your healthcare team can advise on what to do and whether any further care is needed. The most common side effects are headache and constipation. Not everyone who takes it will have these effects. Tell your doctor if any side effect bothers you or does not go away. Ask your doctor or pharmacist about anything unusual you notice after taking Oxipal 0.075 mg/1.5 ml IV, and seek medical help promptly if you have a severe reaction or any symptom that worries you.

Safety and precautions

Do not receive Oxipal 0.075 mg/1.5 ml IV if you are allergic to Palonosetron or any ingredient in the injection. If you are pregnant or breastfeeding, ask your doctor first; the medicine is in pregnancy category B, and it is not known if it passes into breast milk. Only the doctor can decide whether this injection is appropriate for you. Ask your doctor first if any of these apply to you.

Frequently asked questions

What does Oxipal 0.075 mg/1.5 ml IV treat?

It may also be used for nausea and vomiting after surgery. It is an anti-emetic medicine, meaning it acts against nausea and vomiting.

How should I take Oxipal 0.075 mg/1.5 ml IV?

Oxipal 0.075 mg/1.5 ml IV is given as an injection by a doctor or nurse, usually into a vein. Oxipal 0.075 mg/1.5 ml IV is given as an injection by a healthcare professional.

What are the side effects of Oxipal 0.075 mg/1.5 ml IV?

Your healthcare team can advise on what to do and whether any further care is needed. The most common side effects are headache and constipation.

Can I use Oxipal 0.075 mg/1.5 ml IV in pregnancy or while breastfeeding?

Do not receive Oxipal 0.075 mg/1.5 ml IV if you are allergic to Palonosetron or any ingredient in the injection. If you are pregnant or breastfeeding, ask your doctor first; the medicine is in pregnancy category B, and it is not known if it passes into breast milk.

Indications

Palonosetron indicated in-
  • Acute and delayed nausea and vomiting
  • Uncontrolled nausea and vomiting
  • Chemotherapy-induced nausea and vomiting (CINV): Acute CINV resulting in on the day of treatment with certain types of chemotherapy
  • Delayed CINV resulting in on days later with certain types of chemotherapy
  • ... Read more
Palonosetron indicated in-
  • Acute and delayed nausea and vomiting
  • Uncontrolled nausea and vomiting
  • Chemotherapy-induced nausea and vomiting (CINV): Acute CINV resulting in on the day of treatment with certain types of chemotherapy
  • Delayed CINV resulting in on days later with certain types of chemotherapy
  • Radiotherapy-induced nausea and vomiting (RINV)
  • Post-operative & Post-discharge nausea and vomiting (PONV & PDNV).

Pharmacology

Palonosetron is a 5-HT3 receptor antagonist with a strong binding affinity for this receptor and little or no affinity for other receptors. It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine and that the released serotonin then activates 5-HT3 receptors that are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema, to initiate the vomiting reflex. Postoperative nausea and vomiting is influenced by multiple patient, surgical and anesthesia related factorcs and is triggered by release of 5-HT3 in a cascade of neuronal event involving both the central nervous system and the gastrointestinal tract. The 5-HT3 receptor has been demonstrated to selectively participate in the emetic response. Palonosetron works by blocking the actions of Serotonin, associated with nausea and vomiting, at 5-HTs receptor. It is likely that Palonosetron works in the small intestine but it may also work in the brain.

Pharmacokinetics: Palonosetron exhibits linear dose-proportional pharmacokinetics over the doserange 1-90 pg/kg in healthy subjects and in patients with cancer. In cancer patients receiving single intravenous doses of Palonosetron in this dose range, the mean maximum plasma concentration (Cmax) ranges from 0.89 to 336 ng/ml and the area under the plasma concentration-time curve from zero to infinity (AUCo-co) ranges from 13.8 to 957 ng.h/ml. Palonosetron has a volume of distribution of approximately 6.9-7.9 L/kg, with approximately 62% bound to plasma proteins. Approximately 50% of Palonosetron is metabolized into two inactive metabolites that exhibit <1% of the 5-HT3 receptor antagonist activity. Approximately 40% of the drug is metabolised via kidney, 50% by liver CYP2D6 (mainly), CYP3A4 and CYP1A2 isoenzymes. About 50% of the drug goes under metabolism. After a single intravenous dose, approximately 40% is excreted as unchanged drug in the urine after 144 hours. Total body clearance of Palonosetron is 160±35 ml/h/kg, and renal clearance is 66.5±18.2 ml/h/kg in healthy subjects. Palonosetron exhibits a longer half-life (40 hours) and has a greater 5-HT3 receptor binding affinity.

Dosage & Administration

Usual dosage: Adult tablet dosage: 0.5 mg daily. Adult IV dosage: A single IV dose of 0.075 mg should be administered over 10 seconds.

Chemotherapy-induced nausea and vomiting: Adult tablet dosage: 0.5 mg administered approximately 1 hour prior to the start of chemotherapy. Adult IV dosage: A single IV dose of 0.25 mg should be administered over 30 seconds approximately 30 minutes before the start of chemotherapy.

Radiotherapy-induced nausea and vomiting: A single IV dose of 0.25 mg should be administered over 30 seconds approximately 30 minutes before each week of radiation fraction.

Post-operative nausea and vomiting: A single IV dose of 0.075 mg should be administered over 10 seconds immediately before induction of anesthesia.

Children dosage: (1 month to 17 years): A single IV dose at 20 mcg/kg body weight. Which maximum dose is 1.5 mg.

Interaction

In controlled clinical trials, Palonosetron injection has been safely administered with corticosteroids, analgesics, antiemetics/antinauseants, antispasmodics and anticholinergic agents. Palonosetron did not inhibit the antitumor activity of cisplatin, cyclophosphamide, cytarabine, doxorubicin and mitomycin C in murine tumor models. Concomitant administration of Palonosetron and metoclopramide has no significant pharmacokinetic interactions. In vitro studies indicated that palonosetron is not inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP2E1 & CYP3A4/5 (CYP2C19 was not investigated) nor does it induce the activity of CYP1A2, CYP2D6 or CYP3A4/5. Therefore, the potential for clinically significant drug interactions with Palonosetron appears to be low.

Contraindications

Palonosetron is contraindicated in patients known to have hypersensitivity to the drug or any of its components.

Side Effects

The most common adverse reactions are headaches and constipation.

Pregnancy & Lactation

Pregnancy category 'B'. It is not known whether Palonosetron is excreted in breast milk.

Overdose Effects

There is no known antidote to Palonosetron. Overdose should be managed with supportive care.

Storage Conditions

Store in a cool & dry place, protected from light.

Alternative brands of Palonosetron

Other brands with the same generic name, cheapest first.

See all 16 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.